What have we learnt from Vioxx?

被引：167

作者：

Krumholz, Harlan

Ross, Joseph S.

Presler, Amos H.

Egilman, David S.

机构：

[1] Yale Univ, Sch Med, Dept Med, New Haven, CT 06520 USA

[2] Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY USA

[3] Never Again Consulting, Attleboro, MA USA

[4] Brown Univ, Dept Biomed Community Hlth, Providence, RI 02912 USA

来源：

BMJ-BRITISH MEDICAL JOURNAL | 2007年 / 334卷 / 7585期

关键词：

D O I：

10.1136/bmj.39024.487720.68

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In October UK patients who had cardiovascular events while taking rofecoxib lost the right to fight Merck in the US for compensation. But researchers and journals can still benefit from this case if they learn from the mistakes, write Harlan Krumholz and colleagues.

引用

收藏

页码：120 / 123

页数：8

相关论文

共 59 条

[1] Cyclooxygenase inhibition and cardiovascular risk [J].

Antman, EM ;

DeMets, D ;

Loscalzo, J .

CIRCULATION, 2005, 112 (05) :759-770

[2]

Berenson Alex, 2004, N Y Times Web, pA32

[3] Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. [J].

Bombardier, C ;

Laine, L ;

Reicin, A ;

Shapiro, D ;

Burgos-Vargas, R ;

Davis, B ;

Day, R ;

Ferraz, MB ;

Hawkey, CJ ;

Hochberg, MC ;

Kvien, TK ;

Schnitzer, TJ ;

Weaver, A .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (21) :1520-1528

[4] Report of specific cardiovascular outcomes of the ADVANTAGE trial [J].

Braunstein, N ;

Polis, A .

ANNALS OF INTERNAL MEDICINE, 2005, 143 (02) :158-159

[5]

Bresalier RS, 2006, NEW ENGL J MED, V355, P221

[6] Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [J].

Bresalier, RS ;

Sandler, RS ;

Quan, H ;

Bolognese, JA ;

Oxenius, B ;

Horgan, K ;

Lines, C ;

Riddell, R ;

Morton, D ;

Lanas, A ;

Konstam, MA ;

Baron, JA .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) :1092-1102

[7] Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison [J].

Cannon, Christopher P. ;

Curtis, Sean P. ;

FitzGerald, Garret A. ;

Krum, Henry ;

Kaur, Amarjot ;

Bolognese, James A. ;

Reicin, Alise S. ;

Bombardier, Claire ;

Weinblatt, Michael E. ;

van der Heijde, Desiree ;

Erdmann, Erland ;

Laine, Loren .

LANCET, 2006, 368 (9549) :1771-1781

[8]

Catella-Lawson F, 1999, J PHARMACOL EXP THER, V289, P735

[9] Expression of concern reaffirmed [J].

Curfman, GD ;

Morrissey, S ;

Drazen, JM .

NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (11) :1193-1193

[10] Expression of concern: Bombardier et al., "Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis," N Engl J Med 2000;343:1520-8 [J].

Curfman, GD ;

Morrissey, S ;

Drazen, JM .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (26) :2813-2814

← 1 2 3 4 5 6 →